文献速递急性肾损伤

急性肾损伤后使用肾素-血管紧张素系统阻滞剂与复发性AKI风险

Renin-Angiotensin System Blockade after Acute Kidney Injury (AKI) and Risk of Recurrent AKI.
PubMed 文献 · Clin J Am Soc Nephrol · 2019-12-16

本研究为回顾性队列,纳入10242例住院AKI存活且无心衰或既往ACEI/ARB使用的患者,分析出院后新用ACEI/ARB与复发性住院AKI的关系。中位随访3年,调整基线及时间依赖混杂后,ACEI/ARB使用与复发性AKI风险升高无关(aOR 0.71,95%CI 0.45-1.12)。

要点

  • AKI存活且无心衰者新用ACEI/ARB未独立增加复发性住院AKI风险。
  • 复发性AKI粗发生率用药与否相近(5.7 vs 6.1/100人年)。

核心结论

  • 在无心衰的AKI存活者中,新使用ACEI/ARB治疗未独立增加复发性住院AKI风险。

研究设计与样本

  • 回顾性队列研究,纳入2006年1月1日至2013年12月31日期间住院AKI存活且无心衰或既往ACEI/ARB使用的10242例患者,采用边际结构模型调整基线及时间依赖混杂。

主要发现

  • 中位随访3年(IQR 1-5),1853例(18%)启动ACEI/ARB,2124例(21%)发生复发性AKI。
  • 复发性AKI粗发生率:未用ACEI/ARB为6.1/100人年(95%CI 5.9-6.4),使用ACEI/ARB为5.7/100人年(95%CI 4.9-6.5)。
  • 调整后ACEI/ARB使用与复发性AKI无显著关联(aOR 0.71,95%CI 0.45-1.12)。

临床怎么用

  • 对于无心衰的AKI存活者,出院后新启用ACEI/ARB无需因担心复发性AKI而过度回避,但仍需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: How to best medically manage patients who survived hospitalized AKI is unclear. Use of renin-angiotensin system blockers in this setting may increase risk of recurrent AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is a cohort study of 10,242 members of an integrated health care delivery system in Northern California who experienced AKI and survived a hospitalization between January 1, 2006 and December 31, 2013. All study participants did not have prior heart failure or use of angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) up to 5 years prior. New receipt and time-updated exposure of ACE-Is/ARBs was identified on the basis of dispensed prescriptions found in outpatient health plan pharmacy databases. The main outcome of interest was subsequent episode of hospitalized AKI after discharge from an initial index hospitalization complicated by AKI. Recurrent AKI episode was defined using acute changes in serum creatinine concentrations. Marginal structural models were used to adjust for baseline and potential time-dependent confounders. RESULTS: Forty-seven percent of the study population had a documented eGFR<60 ml/min per 1.73 m2 or documented proteinuria before hospitalization. With a median of 3 (interquartile range, 1-5) years of follow-up, 1853 (18%) patients initiated use of ACE-Is/ARBs and 2124 (21%) patients experienced recurrent AKI. Crude rate of recurrent AKI was 6.1 (95% confidence interval [95% CI], 5.9 to 6.4) per 100 person-years off ACE-Is/ARBs and 5.7 (95% CI, 4.9 to 6.5) per 100 person-years on ACE-Is/ARBs. In marginal structural causal inference models that adjusted for baseline and potential time-dependent confounders, exposure to ACE-I/ARB use was not associated with higher incidence of recurrent AKI (adjusted odds ratio, 0.71; 95% CI, 0.45 to 1.12). CONCLUSIONS: In this study of AKI survivors without heart failure, new use of ACE-I/ARB therapy was not independently associated with increased risk of recurrent hospitalized AKI.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Hsu CY, Liu KD, Yang J, et al. Renin-Angiotensin System Blockade after Acute Kidney Injury (AKI) and Risk of Recurrent AKI. Clin J Am Soc Nephrol. 2019. PMID: 31843974. doi:10.2215/CJN.05800519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。